EGFR and non-small cell lung carcinoma: NSCLC patients with EGFR somatic mutations, such as exon 19 deletions, nucleotide substitutions including Gly719X (G719X) in exon 18, Ser768Ile (S768I) in exon 20, Leu861Gln (L861Q), and Leu858Arg (L858R) missense mutations in exon 21, are therapeutically treated with an EGFR-TKI inhibitor, gefitinib [7, 8, 11].